Share on LinkedInShare on LinkedIn

ARTICLE · 29 JUNE 2011

Supreme Court Decision Alert - June 23, 2011

Mayer Brown
Mayer Brown
Contributor
Mayer Brown

Mayer Brown

Mayer Brown is a leading international law firm positioned to represent the world’s major...

View firm profile
Explore more from Mayer Brown

In a trilogy of closely watched cases, "PLIVA, Inc. v. Mensing", No. 09-993, "Activas Elizabeth, LLC v. Mensing", No. 09-1039, and "Activas, Inc. v. Demahy", No. 09-1501, the Supreme Court held today that the federal statutes and regulations governing the labeling of generic drugs preempt state-law failure-to-warn claims against generic drug manufacturers.

United StatesLitigation, Mediation & Arbitration

Originally published June 23, 2011

Keywords: generic drugs, failure-to-warn claims, first amendment, commercial speech, prescription data, federal employers' liability act, prescriber-data statute

Today the Supreme Court issued four decisions, described below, of interest to the business community.

  • Generic Drugs—Food, Drug, and Cosmetic Act—Preemption of Failure-To-Warn Claims
  • First Amendment—Commercial Speech—Use of Prescription Data
  • Bankruptcy—Bankruptcy Court Jurisdiction
  • Federal Employers' Liability Act—Proximate Causation

Generic Drugs—Food, Drug, and Cosmetic Act—Preemption of Failure-To-Warn Claims

PLIVA, Inc. v. Mensing, No. 09-993 (previously discussed in the December 13, 2010 docket report).

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

See more popular content from